aTyr Pharma regains global rights to efzofitimod after Kyorin termination

aTYR PHARMA INC

Kyorin terminated collaboration; aTyr and Kyorin entered termination agreement effective July 30, 2026.
Exclusive rights to develop and commercialize efzofitimod in Japan revert to aTyr.
aTyr now holds global rights to efzofitimod for all forms of interstitial lung disease.
Termination includes wind-down of ancillary agreements and transfer of data and orphan drug designation.
No outstanding payments from Kyorin to aTyr regarding development costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.